September 2025 in “e-space (Manchester Metropolitan University)” Blocking androgen receptors helps immune cells better fight certain bacteria.
3 citations
,
March 2020 in “The Journal of Urology” Older patients sticking to their prostate medication saw lasting health benefits.
11 citations
,
February 2016 in “Current Medicinal Chemistry” New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.
16 citations
,
June 2018 in “JAAD case reports” A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
June 2014 in “Dermatology Times E-News” An arthritis drug helped a person with severe hair loss regrow their hair.
17 citations
,
January 1993 in “Journal of Gastroenterology and Hepatology” Interferon α‐2b can temporarily reduce hepatitis C virus and normalize liver enzyme levels.
June 2024 in “Journal of Clinical Oncology” EGFR-TKIs can cause unexpected skin, nail, and hair issues.
14 citations
,
November 2008 in “Expert opinion on drug metabolism & toxicology” Finasteride helps treat prostate issues and may prevent prostate cancer in high-risk men.
23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
39 citations
,
January 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
April 2020 in “The FASEB journal” Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
May 2025 in “Journal of medical and dental science research.” i-PRF and A-PRF are promising treatments for hair regrowth in androgenetic alopecia.
6 citations
,
May 2020 in “JAMA Ophthalmology” Using 5-alpha-reductase inhibitors, drugs for prostate issues and hair loss, may lead to eye abnormalities in men.
September 2025 in “Journal of the American Academy of Dermatology” Using 5α-reductase inhibitors for hair loss in women doesn't increase cancer risk.
January 2024 in “Wiadomości Lekarskie” The ABI1 gene contributes to prostate cancer progression and treatment resistance.
16 citations
,
October 1994 in “The Journal of Steroid Biochemistry and Molecular Biology” Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.
7 citations
,
March 2015 in “The American Journal of the Medical Sciences” Finasteride helps reduce blood vessel growth in diabetic rat kidneys.
January 1978 in “Enlighten: Theses (The University of Glasgow)” Inhibiting testosterone 5alpha-reductase may help treat benign prostatic hyperplasia.
1 citations
,
December 2012 in “I P Pavlov Russian Medical Biological Herald” Finasteride increases P-glycoprotein activity in the liver and kidney.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
2 citations
,
December 2015 in “DOAJ (DOAJ: Directory of Open Access Journals)” Targeted anticancer therapies often cause skin issues, affecting treatment adherence and quality of life.
3 citations
,
January 2001 in “Cambridge University Press eBooks” Finasteride effectively treats hair loss and enlarged prostate in men, with mild side effects.
1 citations
,
September 2022 in “Sudan Journal of Medical Sciences” Danoprevir, remdesivir, and saridegib may effectively inhibit SARS-CoV-2.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
May 2025 in “Immunotherapy” Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.
November 2025 in “Russian Journal of Oncology” Modifying steroidal inhibitors shows promise for developing new cancer treatments.
November 2021 in “Pharmaceutical Sciences” New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.
52 citations
,
July 1998 in “Urology” Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.
January 2019 in “프로그램북(구 초록집)” Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.